The "Abdominal Aortic Aneurysm - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Abdominal Aortic Aneurysm Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Abdominal Aortic Aneurysm market. A detailed picture of the Abdominal Aortic Aneurysm pipeline landscape is provided, which includes the disease overview and Abdominal Aortic Aneurysm treatment guidelines.
The assessment part of the report embraces in-depth Abdominal Aortic Aneurysm commercial assessment and clinical assessment of the Abdominal Aortic Aneurysm pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abdominal Aortic Aneurysm collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Abdominal Aortic Aneurysm with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Abdominal Aortic Aneurysm treatment.
- Abdominal Aortic Aneurysm key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Abdominal Aortic Aneurysm market.
Scope of the Report
- The Abdominal Aortic Aneurysm report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Abdominal Aortic Aneurysm across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Abdominal Aortic Aneurysm therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Abdominal Aortic Aneurysm research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Abdominal Aortic Aneurysm.
Key Topics Covered
1. Report Introduction
2. Abdominal Aortic Aneurysm
2.3. Abdominal Aortic Aneurysm Symptoms
2.6. Abdominal Aortic Aneurysm Diagnosis
2.6.1. Diagnostic Guidelines
3. Abdominal Aortic Aneurysm Current Treatment Patterns
3.1. Abdominal Aortic Aneurysm Treatment Guidelines
4. Abdominal Aortic Aneurysm - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Abdominal Aortic Aneurysm companies collaborations, Licensing, Acquisition -Deal Value Trends
22.214.171.124. Assessment Summary
4.1.2. Abdominal Aortic Aneurysm Collaboration Deals
126.96.36.199. Company-Company Collaborations (Licensing / Partnering) Analysis
188.8.131.52. Company-University Collaborations (Licensing / Partnering) Analysis
184.108.40.206. Abdominal Aortic Aneurysm Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
220.127.116.11. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
18.104.22.168. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
22.214.171.124. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
126.96.36.199. Assessment by Stage and MOA
5.1.6. Assessment by Target
188.8.131.52. Assessment by Stage and Target
6. Abdominal Aortic Aneurysm Late Stage Products (Phase-III)
7. Abdominal Aortic Aneurysm Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Abdominal Aortic Aneurysm Discontinued Products
13. Abdominal Aortic Aneurysm Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
184.108.40.206. Product Overview
220.127.116.11. Mechanism of action
13.1.2. Research and Development
18.104.22.168. Clinical Studies
13.1.3. Product Development Activities
22.214.171.124. Patent Detail
13.1.4. Tabulated Product Summary
126.96.36.199. General Description Table
14. Abdominal Aortic Aneurysm Key Companies
15. Abdominal Aortic Aneurysm Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Abdominal Aortic Aneurysm Unmet Needs
18. Abdominal Aortic Aneurysm Future Perspectives
19. Abdominal Aortic Aneurysm Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
- Faron Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ux3r7b
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900